Lupus (SLE) trials in Canada

In Canada 19 Also abroad 354

19 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Where
Calgary, Hamilton, Richmond, Toronto, Winnipeg
Age
18 years to 70 years
People
245 worldwide
Run by
AstraZeneca
See details and how to joinNCT07430306
Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Québec, Toronto
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 3Taking people
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Where
Rimouski, Toronto, Vancouver
Age
12 years to 100 years
People
550 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Where
Kelowna
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00
Phase 2Taking people
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Where
Montreal, Toronto
Age
5 years to 17 years
People
40 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05039619 · EU 2023-505825-15-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Where
Québec, Rimouski, Toronto
Age
16 years and over
People
450 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00
Phase 1Taking people
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Where
Montreal
Age
18 years to 74 years
People
66 worldwide
Run by
Allogene Therapeutics
See details and how to joinNCT07085104
No phaseTaking people
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Where
Calgary, London, Ottawa, Sherbrooke, Toronto
Age
16 years and over
People
223 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07175285
Phase 1Taking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Hamilton, Sherbrooke
Age
18 years to 70 years
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
Phase 3Enrolling by invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Where
Calgary, Edmonton AB, Rimouski, Toronto
Age
16 years and over
People
760 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00
Phase 1/2Taking people
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Where
Montreal
Age
12 years to 65 years
People
28 worldwide
Run by
Cabaletta Bio
See details and how to joinNCT06121297 · EU 2023-507613-10-01
Phase 1Taking people
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Where
Toronto
Age
18 years and over
People
300 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT03816345
Phase 3Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Where
Toronto
Age
18 years and over
People
864 worldwide
Run by
Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00
Phase 3Taking people
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Where
Calgary, Toronto, Vancouver
Age
5 years to 17 years
People
100 worldwide
Run by
AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00
Phase 1Enrolling by invitation
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Where
Montreal, Ottawa
Age
18 years and over
People
52 worldwide
Run by
Kite, A Gilead Company
See details and how to joinNCT07038447
Phase 1/2Taking people
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Where
Toronto
Age
18 years to 70 years
People
150 worldwide
Run by
AstraZeneca
See details and how to joinNCT06897930
No phaseTaking people
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
Where
Toronto
Age
18 years to 45 years
People
700 worldwide
Run by
Hospital for Special Surgery, New York
See details and how to joinNCT00198068
No phaseTaking people
Lupus Landmark Study: A Prospective Registry and Biorepository
Where
Calgary, Edmonton, Montreal, Québec, Toronto, Winnipeg
Age
18 years to 110 years
People
3,500 worldwide
Run by
Lupus Research Alliance
See details and how to joinNCT05934149
No phaseTaking people
Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus
Where
Toronto
Age
12 years to 22 years
People
175 worldwide
Run by
Michigan State University
See details and how to joinNCT06232304